SCHEMBL26768366

SCHEMBL26768366

COC(=O)C(C)C(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.44
CA14 Q9ULX7 1/20 0.44
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
SYK P43405 1/20 0.40
SERPINE1 P05121 1/20 0.40
CA7 P43166 1/20 0.40
CTSS P25774 3/20 0.39
CTSK P43235 3/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CA9 Q16790 2/20 0.38
PSENEN Q9NZ42 1/20 0.38
PCSK9 Q8NBP7 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642189 1.00 CA12 (0.44) CA12CA14MEN1GAAKMT2A
SCHEMBL26640126 0.84 KMT2A (0.51) MEN1GAAKMT2ATDP1CA1
SCHEMBL15506070 0.84 KMT2A (0.51) MEN1GAAKMT2ATDP1CA1
SCHEMBL24257004 0.83 CA12 (0.42) CA12CA14MEN1GAAKMT2A
SCHEMBL85950 0.82 CA12 (0.46) CA12CA14MEN1GAAKMT2A
SCHEMBL29689259 0.82 CA12 (0.46) CA12CA14MEN1GAAKMT2A
SCHEMBL1262051 0.82 CA12 (0.46) CA12CA14MEN1GAAKMT2A
SCHEMBL1262055 0.82 CA12 (0.46) CA12CA14MEN1GAAKMT2A
SCHEMBL8366813 0.82 CA1 (0.49) CA12MEN1GAAKMT2ATDP1
SCHEMBL18257278 0.81 CA12 (0.40) CA12CA14MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522591-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-03-19 EP disclosed
CN-119212978-A Oxoindolinyl amide derivatives for inhibiting NLRP3 and use thereof 万特斯治疗美国公司 2024-12-27 CN disclosed
US-20240368131-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2024-11-07 US disclosed
WO-2023220715-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2023-11-16 WO disclosed
WO-2023220715-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368131-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NLRP3, NLRP1, NOD1 CA12 4403/4885CA14 4609/4885MEN1 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.